Start with its own history
At 35.13×, CRL is 73.2% below its 9-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
NYSE · CRLMedical - Diagnostics & ResearchUpdated Nov 2, 2026
Charles River Laboratories International, Inc. P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
35.13×
73.2% belowthe 9-observation annual average
Share price347.78
÷Earnings per share9.9
Price and EPS in quote currency. Calculation details
Investors are paying 35.13 for every 1 of reported earnings per share.
P/E over time
2016 – 2025
Annual P/ESelected-period average 131.15×
3-year average478.15×2 positive annual observations
5-year average256.89×4 positive annual observations
10-year average131.15×9 positive annual observations
Peer median · TTM35.23×7 peers with positive P/E
Historical P/E ratios
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 27, 2025 | N/M | N/M |
| Dec 28, 2024 | 930.80× | +3550.0% |
| Dec 31, 2023 | 25.50× | +12.0% |
| Dec 31, 2022 | 22.77× | -53.0% |
| Dec 31, 2021 | 48.49× | +42.6% |
| Dec 31, 2020 | 33.99× | +15.1% |
| Dec 31, 2019 | 29.55× | +23.2% |
| Dec 31, 2018 | 23.98× | -43.0% |
View all 25 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2017 | 42.10× | +81.8% |
| Dec 31, 2016 | 23.16× | -7.5% |
| Dec 31, 2015 | 25.04× | +7.0% |
| Dec 31, 2014 | 23.40× | -5.2% |
| Dec 31, 2013 | 24.67× | +33.7% |
| Dec 31, 2012 | 18.46× | +45.9% |
| Dec 31, 2011 | 12.65× | N/M |
| Dec 31, 2010 | N/M | N/M |
| Dec 31, 2009 | 19.25× | N/M |
| Dec 31, 2008 | N/M | N/M |
| Dec 31, 2007 | 28.48× | N/M |
| Dec 31, 2006 | N/M | N/M |
| Dec 31, 2005 | 20.77× | -18.3% |
| Dec 31, 2004 | 25.42× | +30.3% |
| Dec 31, 2003 | 19.51× | -43.2% |
| Dec 31, 2002 | 34.36× | -11.7% |
| Dec 31, 2001 | 38.93× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How CRL compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 CRL This stockCharles River Laboratories International, Inc. | 35.13× |
 MEDPMedpace Holdings, Inc. | 35.34× |
 ICLRICON Public Limited Company | 35.23× |
 WUXIFWuXi AppTec Co., Ltd. | 15.10× |
 603127.SSJoinn Laboratories(China)Co.,Ltd. | 28.69× |
 300759.SZPharmaron Beijing Co., Ltd. | 43.19× |
 WXIBFWuXi Biologics (Cayman) Inc. | 31.22× |
 2268.HKWuXi XDC Cayman Inc | 45.86× |
 GNNSFGenscript Biotech Corporation | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does CRL’s P/E tell you?
Compare like with like
The median of the 7 positive peer ratios above is 35.23×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take CRL into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("CRL", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 347.78 ÷ EPS 9.9 = 35.13×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 2, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
CRL P/E ratio: common questions
The essentials behind the numbers.
Charles River Laboratories International, Inc.'s current P/E is 35.13× based on the quote data last updated Nov 2, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.